Table 1.

Demographics and Clinical Outcomes of Biliary Atresia Patients in Parenteral Nutrition and Non-Parenteral Nutrition Groups

All Patients	PN Group (n=25)	Non-PN Group (n=22)
	n (%)	n (%)	p value
Sex
Female	19 (76%)	16 (73%)	1
Ethnicity
Caucasian	15 (60%)	12 (54%)
Hispanic	8 (32%)	6 (27%)
Other	2 (8%)	4 (18%)	0.65
	Mean (SE)	Mean (SE)	p value
Age at HPE (months)	2.1 (0.1)	2.3 (0.2)	0.48
Age at Listing (months)	8.9 (1.0)	9.4 (1.7)	0.82
Age at Clinical Endpoint (months)	12.5 (1.2)	13.6 (1.9)	0.63
Transplanted Patients	PN group n=22	Non-PN Group n=20
	Mean (SE)	Mean (SE)	p value
Time from Listing to Transplant (months)	4 (1.1)	4 (0.8)	1
Calculated PELD score at Liver Transplant	18 (2.6)	14.2 (2.1)	0.24
Age at Liver Transplant (months)	12.9 (1.4)	12.7 (2.0)	0.91
Time in ICU after Transplant (days)	9.1 (1.9)	8.9 (2.7)	0.93
	n (%)	n (%)	p value
Donor Organ Type
Cadaveric Whole	7 (32%)	8 (40%)
Cadaveric Split	5 (23%)	2 (10%)
Cadaveric Reduced	10 (45%)	10 (50%)	0.6
Immunosuppression
Cyclosporine*	14 (64%)	16 (80%)	0.31
Tacrolimus*	8 (36%)	4 (20%)	0.31
Corticosteroids**	22 (100%)	20 (100%)	1
Mycophenolate Mofetil**	10 (45%)	7 (35%)	0.54
Number of Patients Re-Transplanted	1 (5%)	2 (9%)	0.49

^*Initial post-transplant calcineurin inhibitor

^**number (%) of patients receiving medication during the first 6 months post-transplant

PN = parenteral nutrition

HPE = hepatoportoenterostomy

PELD = Pediatric End-Stage Liver Disease